Editorial: Molecular Biomarkers for Gastric Cancer.
作者信息
Hong Xinqiang, Liu Fenglin
机构信息
Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
出版信息
Front Oncol. 2022 Feb 3;12:850373. doi: 10.3389/fonc.2022.850373. eCollection 2022.
Abstract
摘要
相似文献
1
Editorial: Molecular Biomarkers for Gastric Cancer.社论：胃癌的分子生物标志物
Front Oncol. 2022 Feb 3;12:850373. doi: 10.3389/fonc.2022.850373. eCollection 2022.
2
Prognostic significance of CD44 in human colon cancer and gastric cancer: Evidence from bioinformatic analyses.CD44在人类结肠癌和胃癌中的预后意义：来自生物信息学分析的证据。
Oncotarget. 2016 Jul 19;7(29):45538-45546. doi: 10.18632/oncotarget.9998.
3
Novel Biomarkers of Gastric Adenocarcinoma: Current Research and Future Perspectives.胃腺癌的新型生物标志物：当前研究与未来展望
Cancers (Basel). 2021 Nov 12;13(22):5660. doi: 10.3390/cancers13225660.
4
COL1A2 is a Novel Biomarker to Improve Clinical Prediction in Human Gastric Cancer: Integrating Bioinformatics and Meta-Analysis.COL1A2是一种用于改善人类胃癌临床预测的新型生物标志物：整合生物信息学与荟萃分析
Pathol Oncol Res. 2018 Jan;24(1):129-134. doi: 10.1007/s12253-017-0223-5. Epub 2017 Apr 11.
5
Predictive biomarkers along gastric cancer pathogenetic pathways.沿胃癌致病途径的预测性生物标志物。
Expert Rev Anticancer Ther. 2017 May;17(5):417-425. doi: 10.1080/14737140.2017.1301207. Epub 2017 Mar 15.
6
Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers.骨桥蛋白作为胃癌和肝癌的潜在生物标志物和治疗靶点。
World J Gastroenterol. 2012 Aug 14;18(30):3923-30. doi: 10.3748/wjg.v18.i30.3923.
7
Comparison of Prognostic MicroRNA Biomarkers in Blood and Tissues for Gastric Cancer.胃癌血液和组织中预后性微小RNA生物标志物的比较
J Cancer. 2016 Jan 1;7(1):95-106. doi: 10.7150/jca.13340. eCollection 2016.
8
Comprehensive analysis of prognostic genes in gastric cancer.胃癌预后相关基因的综合分析。
Aging (Albany NY). 2021 Oct 22;13(20):23637-23651. doi: 10.18632/aging.203638.
9
Overexpression of CLC-3 is regulated by XRCC5 and is a poor prognostic biomarker for gastric cancer.CLC-3 的过表达受 XRCC5 调控，是胃癌预后不良的生物标志物。
J Hematol Oncol. 2018 Sep 14;11(1):115. doi: 10.1186/s13045-018-0660-y.
10
Heat Shock Factor 1 as a Prognostic and Diagnostic Biomarker of Gastric Cancer.热休克因子1作为胃癌的预后和诊断生物标志物
Biomedicines. 2021 May 21;9(6):586. doi: 10.3390/biomedicines9060586.
引用本文的文献
1
Advances and challenges in gastric cancer testing: the role of biomarkers.胃癌检测的进展与挑战：生物标志物的作用
Cancer Biol Med. 2025 Mar 24;22(3):212-30. doi: 10.20892/j.issn.2095-3941.2024.0386.
2
Stem Cell Biomarkers and Tumorigenesis in Gastric Cancer.胃癌中的干细胞生物标志物与肿瘤发生
J Pers Med. 2022 Jun 3;12(6):929. doi: 10.3390/jpm12060929.
本文引用的文献
1
Current treatment and recent progress in gastric cancer.胃癌的当前治疗方法和最新进展。
CA Cancer J Clin. 2021 May;71(3):264-279. doi: 10.3322/caac.21657. Epub 2021 Feb 16.
2
Incorporating molecular biomarkers into clinical practice for gastric cancer.将分子标志物纳入胃癌的临床实践中。
Expert Rev Anticancer Ther. 2019 Sep;19(9):757-771. doi: 10.1080/14737140.2019.1659136. Epub 2019 Aug 26.
3
Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study.帕妥珠单抗联合曲妥珠单抗和化疗治疗人表皮生长因子受体 2 阳性转移性胃或胃食管交界腺癌（JACOB）：一项双盲、随机、安慰剂对照的 3 期研究的最终分析。
Lancet Oncol. 2018 Oct;19(10):1372-1384. doi: 10.1016/S1470-2045(18)30481-9. Epub 2018 Sep 11.
4
Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.拉帕替尼联合卡培他滨和奥沙利铂治疗人表皮生长因子受体 2 阳性的晚期或转移性胃、食管或胃食管交界腺癌：TRIO-013/LOGiC——一项随机 III 期试验。
J Clin Oncol. 2016 Feb 10;34(5):443-51. doi: 10.1200/JCO.2015.62.6598. Epub 2015 Nov 30.
5
New paradigms in translational science research in cancer biomarkers.癌症生物标志物转化科学研究的新范例。
Transl Res. 2012 Apr;159(4):343-53. doi: 10.1016/j.trsl.2012.01.015. Epub 2012 Feb 3.
6
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.曲妥珠单抗联合化疗与单纯化疗治疗 HER2 阳性晚期胃或胃食管交界腺癌（ToGA）：一项开放标签、随机对照的 3 期临床试验。
Lancet. 2010 Aug 28;376(9742):687-97. doi: 10.1016/S0140-6736(10)61121-X. Epub 2010 Aug 19.
Zotero 插件